疫苗前沿 | 有望带来乙肝功能性治愈全口服治疗方案，RNA去稳定剂完成首例给药

 

参考资料:

[1] Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer. Retrieved August 16, 2021, from https://www.businesswire.com/news/home/20210816005078/en/Enanta-Pharmaceuticals-Doses-First-Subject-in-a-Phase-1-Clinical-Study-of-EDP-721-Its-Oral-Hepatitis-B-Virus-RNA-Destabilizer